Clinical Trial Update: A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas. [Phase 2]

View source ↗

Summary

Phase 2 trial update for an oral LY317615 in relapsed or refractory diffuse large B-cell lymphoma, with completed status and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• LY317615

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-08-10